Key terms
About YMAB
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest YMAB news
Mar 14
9:33am ET
Y-Mabs Therapeutics CFO Resigns, Ensures Smooth Transition
Mar 06
6:13am ET
Y-mAbs Therapeutics price target raised to $22 from $21 at H.C. Wainwright
Mar 04
10:50am ET
Biotech Alert: Searches spiking for these stocks today
Mar 04
8:43am ET
Y-mAbs Therapeutics price target raised to $26 from $16 at BMO Capital
Mar 04
7:36am ET
Y-mAbs Therapeutics appoints Tagliaferri to board of directors
Mar 04
7:32am ET
Y-mAbs Therapeutics price target raised to $26 from $22 at Canaccord
Feb 29
4:23pm ET
Y-mAbs Therapeutics sees FY24 revenue $95M-$100M, consensus $96.27M
Feb 29
4:22pm ET
Y-mAbs Therapeutics reports Q4 EPS (2c), consensus (20c)
Feb 20
6:26am ET
Buy Rating Affirmed for Y-Mabs Therapeutics on SADA Technology’s Promising Radiotherapy Advancements
Feb 20
6:16am ET
Y-mAbs Therapeutics price target raised to $21 from $11 at H.C. Wainwright
Jan 31
10:56am ET
Biotech Alert: Searches spiking for these stocks today
No recent news articles are available for YMAB
No recent press releases are available for YMAB
YMAB Financials
Key terms
Ad Feedback
YMAB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
YMAB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range